Friday, September 11, 2026

AI Terminator Fears Grow & Rates Breach 4.9% | The Weekly Wrap

Ten-year Treasury yields breach 4.9% as Steve Eisman discusses AI fears, OpenAI's price cut, Oracle's 30% revenue growth and Tesla's robotaxi setback.

TSLA $1.5TNVDA $5.4T

Steve Eisman Sep 11 2 clicks

Sep 11 LULU $11B

Lululemon: The 15-Minute Thesis

Hated Moats 2 clicks

Sep 11 LULU $11B

Why “Affordable Luxury” Doesn't Compound

MBI Deep Dives 2 clicks

From X

@TidefallCapital Sep 11

Trevor Scott on X

I'll never understand going long $ADBE at 14x '27 when you can buy $CSU.TO at 15x '27. Maybe because it's Canadian listed.

@negligible_cap Sep 11

Negligible Capital on X

*NVIDIA IN TALKS TO INVEST UP TO $10B IN ANTHROPIC IPO: REUTERS Anthropic is in talks with $NVDA to bring them on as an anchor investor in the IPO. Probably the least surprising news ever Anthropic is in talks to raise as much as $100B, which would beat out SpaceX Safety or not here they come

@stockgutter Sep 11

SG on X

$EVTL Reducing the exercise price of options awards is so grifty. It eliminates the alignment with shareholders those grants were intended to create in the first place. In the end this dogshit, low-governance co is going to zero so it may not matter here but as a general proposition don't do this!

@negligible_cap Sep 11

Negligible Capital on X

*CORNING ENTERS UP TO $2B EQUITY DISTRIBUTION DEAL $GLW announces a $2B at-the-market offering of common stock. More supply inbound

@negligible_cap Sep 11

Negligible Capital on X

I simply refuse to believe that $ADBE has over 1 billion monthly active users https://t.co/U7tgBRDhM2

@kab604 Sep 11

kab60 on X

@MananaInvesting @AKWilk I'd love for you to lay out the math. Only expensive if you don't understand where Blackrod takes the company (or think it's a dud). It's cheaper than the financially engineered hodgepodge of assets Adam has assembled. $GFR obviously a magnet to value bois/generalists.

@StockJabber Sep 11

Edwin Dorsey on X

@Mike10947310 What do you think of Edenbrook selling off some of its $FEIM position in August? https://t.co/YOsXfjCnr4

@KEDM_COM Sep 11 2 clicks

KEDM.com on X

Deckers Outdoor $DECK increased its buyback authorization by $3.5bn to $5bn. Not bad for a ~$11bn market cap. And it makes sense: msd-hsd topline growth, >20% EBITDA margins, over 70% FCF conversion, strong and rapidly increasing net cash position. They bought back ~6.5% of s/o last year. 10x EV/EBITDA seems too low.

The Five Deals That Made Apollo

Apollo Global Management’s five defining deals, from Executive Life to Intel, built a $1 trillion asset manager spanning insurance and…

APO $73B

Net Interest Sep 11 1 click

In Conversation: NVIDIA

NVIDIA sees inference, agentic workloads and robotics broadening AI compute demand beyond hyperscalers, while high-speed memory shortages…

NVDA $5.4T

Aurelion Research Sep 11 1 click

Apple: Why iPhone Duo Will Likely Dominate The Foldables Market

Apple’s iPhone Duo foldable pairs a TSMC 2 nm chip, IP68 protection and iOS 27 features, positioning it against Samsung’s Galaxy Z Fold 8.

AAPL $5T

Mark Hibben Sep 11 1 click

Broadcom (NASDAQ: AVGO) Stock Rating: Upgrade To Accumulate From Do Nothing - Accumulation Zone And Stop Inside

Broadcom was upgraded to Accumulate at about $363 after Q3 revenue reached $29.6 billion, with AI semiconductor revenue up 221% to $16.7…

AVGO $1.7T

Cestrian Capital Research. Sep 11

TSOH Weekly Roundup (09/11/2026)

TSOH weekly roundup covers Meta’s child-safety settlement, Markel’s leadership transition, Peloton’s gym strategy and an upcoming Alarm.com…

META $1.9TMKL $22B

TSOH Investment Research Sep 11 2 clicks

NET Power (NPWR):

NET Power’s $1.80 shares are paired with January $2 covered calls for 40 cents as the company pivots from carbon capture to Permian…

NPWR $160M

Triple S Special Situations Investing Sep 11 2 clicks

Broadcom Could Be Above $1,000 In 2 Years

Broadcom targets $230 billion in AI revenue by 2028 as custom XPUs and multiyear orders from Anthropic, OpenAI and Meta drive growth.

AVGO $1.7T

PropNotes Sep 11 1 click

Applied Materials (NASDAQ: AMAT) Stock Rating: Upgrade To Accumulate After Q3 FY10/26 Earnings - Accumulation Zone And Stop Inside

Applied Materials reported Q3 revenue of $9.1 billion, up 25%, and $2.3 billion in free cash flow as AMAT fell roughly 40% from its June…

AMAT $375B

Cestrian Capital Research. Sep 11

Joby Aviation (NYSE: JOBY) Stock Rating: Accumulate - Initiating Coverage

Joby Aviation is initiated at Accumulate after booking $116m of trailing revenue, forming a Toyota manufacturing venture and agreeing to…

JOBY $6.4B

Cestrian Capital Research. Sep 11

NewtekOne: Pivot Towards Holding Guaranteed Loans A Good Strategy

NewtekOne’s bank conversion and retention of SBA-guaranteed loans target recurring income, while a 6% yield and book-value valuation…

NEWT $337M

Stephen Nemo Sep 11

HRBR · long

Harbor Diversified INC

Harbor Diversified trades at about $0.65 per $1.00 of cash, with at least $150 million in cash as its sole asset.

HRBR $129M

Value Investors Club May 18 1 click

(C)riminally (V)alued (S)caled Healthcare Services

CVS Health fell 20% after cutting 2024 adjusted EPS guidance to $7, but its Aetna insurance and Caremark PBM businesses support a…

CVS $111B

Rod’s Ruminations May 1

A Mexican Blue Chip Bargain

Grupo Herdez, a MXN 15.2 billion Mexican food company, pairs dominant grocery brands with McCormick, Barilla and Hormel joint ventures.

GUZOF $985M

Exploring with Alluvial Capital Mar 7

Nvidia, Nano-X and the interpretation of 13F filings

Nvidia’s $380,000 Nano-X stake came from Zebra Medical Vision’s acquisition and is managed by another reporting person, undermining the 50%…

NNOX $69M

John Hempton's Newsletter Feb 15 2 clicks

Quality Investing Outside the Blue Chips

Rand Worldwide, an Autodesk reseller, grew revenue from $116 million to $306 million while using less equity; expired three-year…

RWWI $400M

Exploring with Alluvial Capital Dec 26

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $2.2B

John Hempton's Newsletter Oct 31 1 click

A Value Trap, an Ancient Stock Pitch, a Glimpse Into The Past

Four Corners’ insider-backed asset sale cut shareholder proceeds to roughly 80% of its prior share price. A 2016 Wilh.

FCPT $2.7B

Exploring with Alluvial Capital Sep 27

Does anyone remember when Alnylam went up 50 percent in a day on a phase three result

Alnylam’s 2022 50% phase-three gain faces FDA advisory-panel scrutiny over its amyloidosis drug’s label extension.

ALNY $33B

John Hempton's Newsletter Sep 12

Essex Biotechnology (1061 HK) - Core products fund investment portfolio

Essex Biotechnology trades at 8 times earnings despite patented Chinese biologics, near-60% niche market share and a portfolio built with…

PFE $161B

Healthy Stock Picks Apr 5

Friday, September 11, 2026

AI Terminator Fears Grow & Rates Breach 4.9% | The Weekly Wrap

Lululemon: The 15-Minute Thesis

Why “Affordable Luxury” Doesn't Compound

From X

Trevor Scott on X

Negligible Capital on X

SG on X

Negligible Capital on X

Negligible Capital on X

kab60 on X

Edwin Dorsey on X

KEDM.com on X

Investor Letters

The Five Deals That Made Apollo

In Conversation: NVIDIA

Apple: Why iPhone Duo Will Likely Dominate The Foldables Market

Broadcom (NASDAQ: AVGO) Stock Rating: Upgrade To Accumulate From Do Nothing - Accumulation Zone And Stop Inside

TSOH Weekly Roundup (09/11/2026)

NET Power (NPWR):

Broadcom Could Be Above $1,000 In 2 Years

Applied Materials (NASDAQ: AMAT) Stock Rating: Upgrade To Accumulate After Q3 FY10/26 Earnings - Accumulation Zone And Stop Inside

Joby Aviation (NYSE: JOBY) Stock Rating: Accumulate - Initiating Coverage

NewtekOne: Pivot Towards Holding Guaranteed Loans A Good Strategy

Harbor Diversified INC

(C)riminally (V)alued (S)caled Healthcare Services

A Mexican Blue Chip Bargain

Nvidia, Nano-X and the interpretation of 13F filings

Quality Investing Outside the Blue Chips

Sarepta Risk and the FDA

A Value Trap, an Ancient Stock Pitch, a Glimpse Into The Past

Does anyone remember when Alnylam went up 50 percent in a day on a phase three result

Essex Biotechnology (1061 HK) - Core products fund investment portfolio

Publications we follow

YouTube 4

Blogs 12

Seeking Alpha 30 of 166

X accounts we follow

Investor letters we follow

Sectors

Friday, September 11, 2026

Trevor Scott on X

Negligible Capital on X

SG on X

Negligible Capital on X

Negligible Capital on X

kab60 on X

Edwin Dorsey on X

KEDM.com on X

Investor Letters

Publications we follow

Newsletters 91

YouTube 4

Blogs 12

Seeking Alpha 30 of 166

X accounts we follow

Investor letters we follow

Sectors